Andere Sprachen Clearside Biomedical, Inc.

Aktien

A2ALP6

US1850631045

CLSD

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
1,39 ^USD	+2,96 %		-6,71 %	+18,80 %

13.05.	CLEARSIDE BIOMEDICAL, INC. : HC Wainwright behält die Bewertung Kaufen bei	ZM
09.05.	Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space Injection in Leading Peer-Reviewed Industry Journal, RETINA	22.05.
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®	21.05.
Clearside Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update	09.05.
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference	08.05.
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024	30.04.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors	16.04.
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	16.04.
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Clearside Biomedical Names Victor Chong Chief Medical Officer	18.03.
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18.03.
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	18.03.
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12.03.
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024	29.02.
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering	07.02.
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO	22.01.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14.12.
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	14.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clearside Biomedical, Inc.

Aktien

A2ALP6

US1850631045

CLSD

Andere Sprachen

Filter